GREY:ATBPF - Post by User
Comment by
Benedictuson Feb 05, 2019 10:51am
202 Views
Post# 29320383
RE:News: Bought deal for 20M shares at 0.25.
RE:News: Bought deal for 20M shares at 0.25. this is why its so frustrating to be in early stage companies like ate.v. So much promise and yet, so much dilution! I had thought the next raise (if needed) would be post the upcoming Q2 results and, therefore, far less dilutive than at current prices. Now I understand why the sp was languishing even prior to yesterday's PR despite the commencement of the clincial trial. Super frustrating to be a minnow in the land of shark financiers. 22 - 23 area should be strong support. I continue to hold my position and hope that this is the last raise prior to stellar results and a partnership announcement.
Dec 2018 PR snippet:
Dan Legault, CEO of Antibe, commented, “The exercising of these warrants shows continued confidence by our investors in Antibe’s drug development programs. Furthermore, the gross proceeds together with cash-on-hand fund the balance of our upcoming Phase 2B clinical trial for ATB-346, expected to start in Q1 2019 with results anticipated in Q2 2019.”
current PR snippet: “This strategic financing will allow us to fund additional development activities for ATB-346 that set the stage for Phase 3 development and fulfill key requirements for regulatory progression and approval,” commented Dan Legault, CEO of Antibe. “This should strengthen our position as we advance global partnering discussions later this year in an effort to fully monetize ATB-346 for shareholders.”